Clinical trial · Interventional
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors
NCT02472977CI-TRIAL-00035582CXCessoR4terminatedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Trial terminated because of lack of efficacy in the short term acute phase
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nivolumab | Drug | Nivolumab | ALIAS |
| Ulocuplumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)
- description
- Small cell lung cancer (SCLC)
- interventionNames
- Drug: Ulocuplumab
- Drug: Nivolumab
- type
- ACTIVE_COMPARATOR
- label
- BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)
- description
- Pancreatic cancer (PAC)
- interventionNames
- Drug: Ulocuplumab
- Drug: Nivolumab
Primary outcomes (5)
- measure
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Immune-mediated AEs
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * SCLC or PAC that is advanced or has spread to other parts of the body * Treated with at least one other chemotherapy that did not work or where cancer relapsed * Minimal limitations on activities of daily living as measured by Eastern Cooperative Oncology Group (ECOG) score of 0-1 Exclusion Criteria: * Patients with cancer that spread to the brain * Active, known or suspected autoimmune disease * Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)
References
Publications (0)
Data not yet available
No reference posted for this study.